StockNews.com Downgrades Amneal Pharmaceuticals (NASDAQ:AMRX) to Buy

Amneal Pharmaceuticals (NASDAQ:AMRX) was downgraded by investment analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research report issued on Thursday.

Other equities research analysts also recently issued research reports about the stock. Truist Financial increased their target price on shares of Amneal Pharmaceuticals from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Wednesday, October 2nd. JPMorgan Chase & Co. raised Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 price objective for the company in a research report on Friday, September 6th. Finally, Piper Sandler boosted their target price on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an “overweight” rating in a report on Monday, November 11th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $10.00.

Amneal Pharmaceuticals Trading Up 0.8 %

AMRX stock traded up $0.06 on Thursday, hitting $7.75. The company’s stock had a trading volume of 1,026,292 shares, compared to its average volume of 1,381,090. Amneal Pharmaceuticals has a 1 year low of $5.01 and a 1 year high of $9.48. The stock has a market cap of $2.40 billion, a price-to-earnings ratio of -11.40 and a beta of 1.12. The firm has a 50 day moving average of $8.43 and a two-hundred day moving average of $7.92.

Insider Activity at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, SVP Jason B. Daly sold 43,657 shares of the business’s stock in a transaction on Friday, November 15th. The shares were sold at an average price of $8.61, for a total transaction of $375,886.77. Following the sale, the senior vice president now directly owns 13,665 shares in the company, valued at approximately $117,655.65. The trade was a 76.16 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 26.56% of the stock is owned by insiders.

Hedge Funds Weigh In On Amneal Pharmaceuticals

A number of large investors have recently made changes to their positions in the stock. Rothschild Investment LLC acquired a new position in Amneal Pharmaceuticals during the second quarter worth about $26,000. Gladius Capital Management LP purchased a new stake in shares of Amneal Pharmaceuticals during the 3rd quarter worth approximately $37,000. DekaBank Deutsche Girozentrale acquired a new stake in shares of Amneal Pharmaceuticals in the 2nd quarter worth approximately $42,000. nVerses Capital LLC purchased a new position in Amneal Pharmaceuticals in the 2nd quarter valued at approximately $62,000. Finally, Xponance Inc. purchased a new position in Amneal Pharmaceuticals in the 2nd quarter valued at approximately $65,000. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.